22
The contribution of community pharmacists during the COVID-19 pandemic
Individual Case Management Services
Galenic Formulation
High-Cost Therapy Dispensing and Management (e.g. Oncology, HIV, RA*, MS**)
Medication Review
Dose Administration Aid
Integrated care pathways/protocols or Quality Circles in place with primary care
Medication Reconciliation
Therapeutic Substitution
Home or Nursing Home medication review
Deprescribing (e.g. benzodiaz-epines, antide-pressants)
Data collection on the effectivness of new medicines
Drug dose titration
(e.g. insulin)
8
1
4
5
2
2
3
1
3
1
2
3
1
3
3
24
20
3
18
14
4
7
11
Remunerated by Government/Health Payer
Provided in most pharmacies under contract, agreement or regulation
Provided in some pharmacies as pilot
Number of European countries
*RA - Rheumatoid Arthritis, ** MS - Multiple Sclerosis
PGEU Annual Report 2021
Community pharmacists exemplar role as primary care providers in the COVID-19 pandemic
PGEU Members 2021
PGEU Executive Committee 2021
PGEU Secretariat
A look forward
2021 at a glance
Foreword Alain Delgutte,
PGEU President 2021
X
The contribution of community
pharmacists during the COVID-19